One Reporter’s Life-Altering Psychedelic Trip
7Digest
Robert Draper, a politics reporter, shares his profound experience with Ibogaine, a powerful psychedelic drug illegal in the US but showing promise for treating PTSD and addiction. He learned about it from political figures and explored its scientific basis in neuroplasticity. Draper details his personal motivation, stemming from past trauma, and the logistical challenges of seeking treatment abroad. The journey itself was intense, involving vivid hallucinations and physical sensations, followed by a difficult "gray day" of recovery. He also experienced 5-MeO-DMT, which helped smooth the transition. Draper reflects on the lasting impact of Ibogaine on his self-perception and neuroplasticity, viewing it as a transformative journey of self-discovery.
Outlines
Introduction to Ibogaine and Robert Draper's Experience
The podcast introduces Robert Draper, a politics reporter, and his experience with Ibogaine, an illegal but potentially groundbreaking drug for treating conditions like PTSD and addiction.
Discovering Ibogaine and its Scientific Basis
Robert Draper learned about Ibogaine from political figures advocating for its use in treating veterans. The podcast delves into what Ibogaine is, its origins, and how it works by activating brain rhythms to promote neuroplasticity, a key factor in treating brain disorders and addiction.
The Growing Trend of Psychedelics in Therapy and Ibogaine's Intensity
The increasing interest in psychedelics for therapeutic purposes is discussed, contrasting with traditional medications. Ibogaine is highlighted as a significantly more intense substance than other psychedelics, carrying risks like cardiac arrest and requiring strict medical supervision.
Personal Motivation and Hopes for Transformation
Robert Draper's decision to try Ibogaine was driven by a desire to heal from deep-seated trauma and low self-esteem stemming from his relationship with his deceased brother. He hoped the experience would open emotional pathways and foster self-acceptance.
The Ibogaine Treatment Journey: Logistics and Preparation
Due to its illegality in the US, Draper traveled to Mexico for Ibogaine treatment. The process involved rigorous preparation, including medical screenings and documentaries, at a well-equipped clinic.
The Ibogaine Experience: Hallucinations, Revelations, and Aftermath
Draper describes the intense Ibogaine journey, marked by vivid hallucinations, symbolic imagery, and physical sensations. This was followed by a challenging "gray day" of physical and emotional discomfort, but ultimately led to rejuvenation and profound personal insights, including a subsequent 5-MeO-DMT experience that helped connect past trauma to physical manifestations. The lasting impact on his neuroplasticity and self-regard is explored.
Keywords
Ibogaine
A psychedelic drug derived from the Tabernanth iboga shrub, used in West African ceremonies. Early research suggests it can treat PTSD, addiction, and cognitive decline by promoting neuroplasticity. It is illegal in the US.
Neuroplasticity
The brain's ability to reorganize itself by forming new neural connections. Ibogaine is believed to enhance neuroplasticity, potentially aiding in recovery from brain injuries and neurodegenerative diseases.
Psychedelics in Therapy
The use of psychedelic substances like ketamine, ayahuasca, psilocybin, and MDMA in therapeutic settings to treat mental health conditions. This trend challenges traditional medical approaches.
Trauma
Deeply distressing or disturbing experiences that have a lasting psychological impact. Ibogaine and other psychedelics are being explored for their potential to help individuals process and heal from trauma.
Gray Day
The term used to describe the day following an intense psychedelic experience like Ibogaine, characterized by physical exhaustion, emotional distress, and lingering psychological effects.
5-MeO-DMT
A potent and short-acting psychedelic derived from the Sonoran Desert Toad's secretions. It is known for inducing euphoria and is sometimes used to smooth the after-effects of other psychedelic journeys.
Q&A
What is Ibogaine and what are its potential therapeutic uses?
Ibogaine is a psychedelic drug derived from a West African shrub. Early research suggests it could be a game-changing treatment for conditions like PTSD, addiction, and cognitive decline by promoting neuroplasticity.
How does Ibogaine work, and what is neuroplasticity?
Ibogaine is thought to activate theta rhythms in the brain, promoting neuroplasticity, which is the brain's ability to adapt and form new connections. This can help in treating brain disorders and injuries.
Why is Ibogaine illegal in the United States?
Ibogaine is classified as a Schedule I drug under the Controlled Substances Act, meaning it is considered to have no accepted medical use and a high potential for abuse, similar to LSD.
What was Robert Draper's personal motivation for trying Ibogaine?
Draper was motivated by a desire to address the lingering effects of a troubled relationship with his deceased older brother, which had left him with survivor's guilt and low self-esteem.
What are the logistical challenges of obtaining Ibogaine treatment?
Due to its illegality in the US, individuals typically travel to countries like Mexico for treatment. Clinics can be expensive, and waiting lists are common.
Can you describe the Ibogaine experience itself?
The experience involves intense hallucinations, often described as a film strip of images, and a buzzing sensation throughout the body. It requires complete surrender and can be emotionally challenging.
What is the \"gray day\" and how does one recover from it?
The \"gray day\" is the period of intense physical and emotional discomfort following the Ibogaine trip. Recovery involves rest, and for many, a subsequent feeling of rejuvenation and clarity.
What is 5-MeO-DMT and how does it relate to the Ibogaine experience?
5-MeO-DMT is another potent psychedelic, often used after Ibogaine to induce euphoria and smooth out any lingering rough edges from the primary experience.
Show Notes
The first time Robert Draper heard about the psychedelic drug ibogaine, it was from an unlikely source: the retired U.S. senator Kyrsten Sinema. As a political reporter for The New York Times, Draper often talks to figures like Ms. Sinema. But on this occasion, he said, she wanted to tell him about how she had tried ibogaine, which is illegal in the United States. She’d become such a believer in the drug that she was pushing her home state of Arizona to fund clinical trials for veterans with combat-related trauma.
Draper found that Ms. Sinema wasn’t the only politician to take up the cause. Rick Perry, the former Texas governor, Republican presidential candidate and Trump energy secretary, has also advocated for research into ibogaine in recent years and taken the drug himself. In 2025, because of Mr. Perry’s efforts, Texas became the first state to dedicate public funds to ibogaine research with veterans.
Recent studies of ibogaine at Stanford University and elsewhere suggest that it might prove effective in treating post-traumatic stress disorder, traumatic brain injuries, addiction and a range of other conditions. As Draper reported on ibogaine’s transformative effects on others, he wondered: Could it help him, too?
Today, on “The Sunday Daily,” Natalie Kitroeff talks to Robert Draper about what drew him to travel to Mexico to try ibogaine, and how his trip changed his life.
On Today’s Episode:
Robert Draper (usually) writes about domestic politics for The New York Times.
Background Reading:
It’s an Obscure Psychedelic Used to Treat Trauma. Could It Help Me?
The Long, Strange Trip of Rick Perry
Art Credit: Illustration By Melissa Santamaría
Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Table of contents
United States
